YourChoice Therapeutics Direct Investment Page

YourChoice Therapeutic's most recent presentation was at the 2025 Portfolia Annual Summit - Click Below to view the latest update:

YourChoice Therapeutics develops non-hormonal contraceptives designed to eliminate the risk of negative side effects associated with traditional hormonal contraceptives. The company's contraceptives work by blocking a protein in sperm required for fertilization, enabling customers to use safe birth control options with no side effects for men and women.

SPV Legal Name: Portfolia 2022 SPV 3 LLC (YourChoice SPV) | EIN: 88-2739443

Portfolio Company | In the News

YourChoice Therapeutics Completes Phase 1a Clinical Study for First Hormone-Free Male Birth Control Pill

June 03, 2024

YourChoice Therapeutics Advances Hormone-Free Male Birth Control Pill to Second Human Study
FemTech Insider

October 1, 2024

Performance Overview

Quarterly Reports

The highlights of Q2 2025 updates as provided by the company. Please note all updates provided are confidential and not for distribution. To access the file, use password: Q225YCSPV!

Moving forward, Portfolia will shift from quarterly to semi-annual company updates.

access the report